Trial
NCT06286046
A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Agios Pharmaceuticals, Inc.
Collaborators
—
Condition
Sickle Cell Disease
Intervention
Mitapivat
Why stopped
Withdrawn prior to study start per sponsor decision. No patients were enrolled.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-03